噻托溴铵治疗支气管扩张合并肺部感染的疗效分析
|
摘要
目的:分析噻托溴铵辅助治疗支气管扩张合并肺部感染的临床疗效。方法:将2017年1～12月我院治疗的108例支气管扩张合并肺部感染患者作为研究对象,应用随机数表法分为两组,各54例。对照组接受抗感染、吸氧、气道灌洗等常规对症治疗,观察组加用噻托溴铵治疗。观察两组临床疗效、不良反应及治疗前后肺功能指标、6min步行距离(6MWT)等。结果:与对照组总有效率74.07%相比,观察组总有效率90.74%相对较高,差异有统计学意义(P<0.05);治疗前两组1s用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1占预计值百分比(FEV1%)、6MWT对比,差异无统计学意义(P>0.05);治疗后与对照组FEV1(2.16±0.43)L、FVC(2.79±0.58)L、FEV1%(66.84±11.42)%、6MWT (302.96±40.15)m相比,观察组FEV1(2.79±0.62)L、FVC (3.61±0.74)L、FEV1%(78.92±13.56)%、6MWT(352.01±45.86)m相对较高,差异有统计学意义(P<0.05);两组不良反应发生率7.41%、5.56%相比,差异无统计学意义(P>0.05)。结论:噻托溴铵辅助治疗支气管扩张合并肺部感染安全性较高且疗效确切,利于增强肺功能,提升运动耐力。
Objective:To analyze the clinical efficacy of tiotropium bromide in treatment of bronchiectasis combined with pulmonary infection. Methods:108 patients with bronchiectasis combined with pulmonary infection treated in the hospital from January to December2017 were selected, and they were divided into two groups by random number table, with 54 cases in each group. Control group was given routine treatment with anti-infection, oxygen uptake and tracheal lavage, while observation group was treated with tiotropium bromide. The clinical efficacy, adverse reactions, indexes of pulmonary function, 6-minute walking test(6 MWT) in two groups were observed. Results:The total effective rate of observation group(90.74%) was higher than control group(74.07%)(P<0.05); Before treatment, there was no statistical difference in the forced expiratory volume in one second(FEV1), forced vital capacity(FVC), FEV1%,6 MWT between the two groups(P>0.05); After treatment, the FEV1, FVC, FEV1%, 6 MWT in observation group [(2.79±0.62)L,(3.61±0.74)L,(78.92±13.56)%,(352.01±45.86)m] were higher than control group [(2.16±0.43)L,(2.79±0.58)L,(66.84±11.42)%,(302.96±40.15)m](P<0.05); There was no statistical statistical difference in the incidence of adverse reactions between the two groups(7.41%VS 5.56%)(P >0.05). Conclusion:Tiotropium bromide in treatment of bronchiectasis combined with pulmonary infection is safe and effective, it can enhance pulmonary function and increase exercise tolerance.
Objective:To analyze the clinical efficacy of tiotropium bromide in treatment of bronchiectasis combined with pulmonary infection. Methods:108 patients with bronchiectasis combined with pulmonary infection treated in the hospital from January to December2017 were selected, and they were divided into two groups by random number table, with 54 cases in each group. Control group was given routine treatment with anti-infection, oxygen uptake and tracheal lavage, while observation group was treated with tiotropium bromide. The clinical efficacy, adverse reactions, indexes of pulmonary function, 6-minute walking test(6 MWT) in two groups were observed. Results:The total effective rate of observation group(90.74%) was higher than control group(74.07%)(P<0.05); Before treatment, there was no statistical difference in the forced expiratory volume in one second(FEV1), forced vital capacity(FVC), FEV1%,6 MWT between the two groups(P>0.05); After treatment, the FEV1, FVC, FEV1%, 6 MWT in observation group [(2.79±0.62)L,(3.61±0.74)L,(78.92±13.56)%,(352.01±45.86)m] were higher than control group [(2.16±0.43)L,(2.79±0.58)L,(66.84±11.42)%,(302.96±40.15)m](P<0.05); There was no statistical statistical difference in the incidence of adverse reactions between the two groups(7.41%VS 5.56%)(P >0.05). Conclusion:Tiotropium bromide in treatment of bronchiectasis combined with pulmonary infection is safe and effective, it can enhance pulmonary function and increase exercise tolerance.
引文
[1]杨晓娟,曹官铭,闫霞,等.支气管肺泡灌洗联合局部注药治疗支气管扩张合并感染的临床观察[J].现代生物医学进展,2015,15(13):2515-2517.
[2]戴晓乔,蒋慧,钟平.纤维支气管镜灌洗术治疗支气管扩张合并肺部感染的疗效评价[J].中华全科医学,2017,15(11):1876-1878.
[3]刘茵,夏敏,孙林,等.沙美特罗替卡松联合罗红霉素对老年支气管扩张患者肺功能和炎症因子的影响[J].中国药房,2015,26(3):305-308.
[4]郭伟洪,袁小玲,吕燕华,等.噻托溴铵粉吸入剂治疗支气管扩张并呼吸衰竭的疗效观察[J].临床肺科杂志,2017,22(8):1372-1374.
[5]成人支气管扩张症诊治专家共识编写组.成人支气管扩张症诊治专家共识[J].中华结核和呼吸杂志,2012,35(7):485-492.
[6]陈灏珠.实用内科学[M].第12版,北京:人民卫生出版社,2008:1658.
[7]熊小敏,杨萍.支气管镜下肺泡灌洗法治疗老年支气管扩张合并感染临床疗效观察[J].河北医学,2015,21(8):1417-1419.
[8]张馨心.支气管镜灌洗治疗支气管扩张伴感染病人的疗效观察[J].临床肺科杂志,2015,20(5):913-916.
[9]陈燕.噻托溴铵治疗稳定期支气管扩张伴阻塞性通气功能障碍的临床观察[J].山西医药杂志,2017,46(3):318-320.
[10]邱贞琴,邱贞荣,许加刚,等.慢性阻塞性肺疾病急性加重期患者肺部感染应用噻托溴铵治疗的效果研究[J].中华医院感染学杂志,2015,25(23):5401-5403.
[11]廖晓斌,戴志辉,杨勇琼.噻托溴铵在支气管扩张伴阻塞性通气障碍患者中应用价值探讨[J].临床肺科杂志,2015,20(4):743-744.
[12]黄有环,王瑞光,李志良.噻托溴铵辅助支气管肺泡灌洗用于支气管扩张合并肺部感染的临床观察[J].中国药房,2017,28(20):2813-2816.
[2]戴晓乔,蒋慧,钟平.纤维支气管镜灌洗术治疗支气管扩张合并肺部感染的疗效评价[J].中华全科医学,2017,15(11):1876-1878.
[3]刘茵,夏敏,孙林,等.沙美特罗替卡松联合罗红霉素对老年支气管扩张患者肺功能和炎症因子的影响[J].中国药房,2015,26(3):305-308.
[4]郭伟洪,袁小玲,吕燕华,等.噻托溴铵粉吸入剂治疗支气管扩张并呼吸衰竭的疗效观察[J].临床肺科杂志,2017,22(8):1372-1374.
[5]成人支气管扩张症诊治专家共识编写组.成人支气管扩张症诊治专家共识[J].中华结核和呼吸杂志,2012,35(7):485-492.
[6]陈灏珠.实用内科学[M].第12版,北京:人民卫生出版社,2008:1658.
[7]熊小敏,杨萍.支气管镜下肺泡灌洗法治疗老年支气管扩张合并感染临床疗效观察[J].河北医学,2015,21(8):1417-1419.
[8]张馨心.支气管镜灌洗治疗支气管扩张伴感染病人的疗效观察[J].临床肺科杂志,2015,20(5):913-916.
[9]陈燕.噻托溴铵治疗稳定期支气管扩张伴阻塞性通气功能障碍的临床观察[J].山西医药杂志,2017,46(3):318-320.
[10]邱贞琴,邱贞荣,许加刚,等.慢性阻塞性肺疾病急性加重期患者肺部感染应用噻托溴铵治疗的效果研究[J].中华医院感染学杂志,2015,25(23):5401-5403.
[11]廖晓斌,戴志辉,杨勇琼.噻托溴铵在支气管扩张伴阻塞性通气障碍患者中应用价值探讨[J].临床肺科杂志,2015,20(4):743-744.
[12]黄有环,王瑞光,李志良.噻托溴铵辅助支气管肺泡灌洗用于支气管扩张合并肺部感染的临床观察[J].中国药房,2017,28(20):2813-2816.